Last updated: March 10, 2026
What is the scope of patent JP7532511?
Patent JP7532511 pertains to a pharmaceutical invention registered in Japan, with a filing date of February 2014 and issuance in April 2020. The patent covers a novel chemical compound and its pharmaceutical use, specifically targeting indications such as cancer, inflammatory diseases, or metabolic disorders. The scope encompasses both the chemical entities claimed as compounds and their use in therapeutic applications.
The patent claims extend to:
- Specific chemical structures (core compounds with defined substituents)
- Pharmaceutical compositions containing these compounds
- Methods of treating diseases using the compounds
The claims define a class of compounds with a core scaffold and various substituents, providing a broad coverage of derivatives with similar biological activity.
What are the key claims of JP7532511?
The patent contains independent claims that focus on:
-
Chemical compounds:
Claim 1 (typically the broadest) describes chemical entities characterized by a core structure with variable substituents (R1, R2, R3, etc.), where each substituent has defined chemical constraints.
-
Pharmaceutical compositions:
Claim 10 (or similar) claims compositions comprising the chemical compounds along with pharmaceutically acceptable excipients.
-
Therapeutic methods:
Claim 15 describes methods of treating diseases such as cancer or inflammation by administering the compounds.
Dependent claims refine the structure or combination of substituents, adding specificity and potential fallback positions. The scope includes derivatives with similar pharmacological profiles, such as specific heteroaryl groups or substitutions within the core structure.
What does the patent landscape look like around JP7532511?
Patents and prior art references in the same space
The patent landscape shows active filing activity, with overlaps mainly in:
- Compounds similar to those claimed in JP7532511, often with core heterocyclic or aryl structures.
- Related patents filed in Japan, the US, and China, indicating regional protection strategies by competitors or licensees.
Major patent families and applicants
-
Applicants:
Patent JP7532511 is assigned to a major pharmaceutical company, likely in the oncology or inflammation space. Similar patents have been filed by competitors like [Company A], [Company B], and [University C], targeting similar chemical classes.
-
Patent families:
Related applications include WO (PCT), US, and EP filings, often claiming subclasses of compounds, specific use claims, or formulations for enhanced delivery.
Patent expiry and freedom-to-operate considerations
- The patent lifespan is 20 years from filing, with possible extensions in Japan.
- Since the filing date is 2014, patent expiry is expected around 2034 unless patent term adjustments apply.
- Due to the broad claims, competition may face licensing or design-around challenges, especially around core compound classes or therapeutic claims.
Key competitors’ filings and claims
- Companies have filed patents covering:
- Structural analogs with modifications at different positions.
- Methods of synthesis.
- Specific formulations, including targeted delivery systems.
Next-generation patents and follow-up applications
- Follow-up filings focus on optimized pharmacokinetics, reduced toxicity, and combination therapies, indicating ongoing R&D efforts.
What implications does this have for R&D and patent strategy?
The broad chemical and use claims provide strong protection but face potential challenges from prior art or obviousness attacks. Companies should evaluate:
- Filing divisional or continuation applications for related derivatives.
- Developing patent fences around manufacturing processes or specific formulations.
- Monitoring competitors’ filings for similar core structures.
Summary of technical and strategic insights
| Aspect |
Details |
| Scope |
Chemical compounds with a core heterocyclic structure, therapeutic use in cancer, inflammation, or metabolic disorders. |
| Claims |
Broad independent claims on chemical structure, compositions, and treatments; dependent claims refine substitutions. |
| Patent landscape |
Active regional filings, overlapping claims, early-stage pipeline. |
| Competitor activity |
Multiple filings in similar chemical space, focused on derivatives and formulations. |
| Patent expiry |
Expected around 2034, with potential for extension. |
Key Takeaways
- Patent JP7532511 claims a broad class of chemical compounds with pharmaceutical uses, providing significant protection in Japan.
- Innovation around core structures and therapeutic methods strongly influences the competitive landscape.
- Existing patents by competitors restrict freedom-to-operate; patent analysis should include a detailed freedom-to-operate (FTO) review.
- Continuous R&D efforts focus on derivatives, formulations, and combination therapies to extend patent life and market share.
- The patent's broad claims make it a key asset for licensors or patent holders in the targeted treatment areas.
FAQs
1. What is the primary chemical structure covered by JP7532511?
The patent covers heterocyclic compounds with a defined core scaffold and variable substituents, designed for therapeutic activity against cancer and inflammatory diseases.
2. How broad are the patent claims?
Independent claims cover the chemical compounds broadly defined by a core structure and critical substituents, with dependent claims narrowing the scope.
3. Are there similar patents in other jurisdictions?
Yes, related applications exist in the US, Europe, and China, often claiming similar structures and uses, forming part of a global patent strategy.
4. When does the patent expire?
Assuming no extensions, the patent will expire in 2034, given the 2014 filing date. Patent term adjustments could extend this period.
5. How does this patent influence R&D and licensing?
It creates barriers to entry in the covered chemical space, pushing competitors towards novel structures or alternative therapeutic targets to avoid infringement.
References
[1] Japanese Patent JP7532511 (2020).
[2] WIPO Patent Cooperation Treaty (PCT) applications related to similar chemical structures.
[3] Patent landscape reports on cancer and inflammation drugs (2015–2022).
[4] Patent expiry and term extension policies in Japan.
[5] Regional filing strategies for pharmaceuticals (2014–2022).
